GPCR: Structure Therapeutics Inc - American Depositary Shares

GPCR新闻

• 14:00 Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?
• 22:00 Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term (SEPN)
• 12:19 NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
• 18:21 Structure Therapeutics - A Strong Bet For An Oral GLP-1 Approval Before 2030 (NASDAQ:GPCR)
• 14:19 Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?
• 15:46 How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
• 15:09 LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
• 14:26 Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
• 13:42 LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
• 15:10 Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
• 12:20 The BioRevolution Has Accelerated
• 15:43 Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
• 15:39 How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?
• 14:13 LLY's Retatrutide Nears 2027 Filing With Two More Phase III Wins
• 14:12 How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results?
• 14:42 NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters Now
• 13:51 Does EU Approval of Wegovy Pill Change NVO's Competitive Story?
• 14:11 NVO Rallies 11% in a Month: How Should Investors Play the Stock?
• 12:46 Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry (NYSE:NVO)
• 14:10 LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now?
• 13:12 Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
• 12:49 Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?
• 14:22 Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?
• 14:01 Can Wegovy Pill's Europe Push Help NVO Offset Mounting Pressures?